Researchers reported discovery of a class of potent cross‑neutralizing monoclonal antibodies active against Marburg virus and the related Ravn virus, with results published in npj Viruses. The antibodies target conserved viral epitopes and demonstrated broad neutralization in laboratory assays, providing new leads for both therapeutic development and improved passive‑immunity countermeasures. Authors detailed binding sites and neutralization breadth, suggesting a path to antibody cocktails or engineered biologics that could be rapidly deployed in outbreaks. The finding strengthens the pipeline for filovirus therapeutics beyond Ebola and supports preparedness efforts against high‑consequence hemorrhagic fevers.